News

Rigel Pharmaceuticals (Rigel) has received a milestone payment from Daiichi Sankyo as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which

Eli Lilly and Kowa Pharmaceuticals America (Kowa) have entered into a co-promotion agreement in the US to commercialise Livalo (pitavastatin). Lilly and Kowa have also entered into a

Ligand Pharmaceuticals has completed the acquisition of Neurogen following approval of the transaction by Neurogen stockholders. As a result, Ligand gains a fully funded partnership with Merck &

The Medicines Company has reported the exclusive worldwide licensing of ApoA-I Milano from Pfizer. The company claims that ApoA-I Milano is a naturally occurring variant of a protein

The FDA has approved Sanofi Pasteur’s Fluzone High-Dose, an inactivated influenza virus vaccine for people aged 65 years and older, to prevent disease caused by influenza virus subtypes

Pfizer Canada has reported that following a priority review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through

Novartis is expected to gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of Corthera. Relaxin is currently in

Ablynx has unveiled results from the open label extension of the phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI).

LifeCycle Pharma (LCP) has submitted the phase 3 protocol for LCP-Tacro in de novo kidney transplant recipients, to the FDA. LCP is expected to review the protocol with